Catalyst Pharmaceuticals (NASDAQ:CPRX) versus BeOne Medicines (NASDAQ:ONC) Head-To-Head Comparison

BeOne Medicines (NASDAQ:ONC) and Catalyst Pharmaceuticals (NASDAQ:CPRX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, dividends and valuation.

Profitability

This table compares BeOne Medicines and Catalyst Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	1.38%	5.52%	3.17%
Catalyst Pharmaceuticals	37.36%	40.78%	35.36%

Earnings & Valuation

This table compares BeOne Medicines and Catalyst Pharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$3.81 billion	10.44	-$644.79 million	$0.51	658.04
Catalyst Pharmaceuticals	$578.20 million	4.82	$163.89 million	$1.72	13.19

Catalyst Pharmaceuticals has lower revenue, but higher earnings than BeOne Medicines. Catalyst Pharmaceuticals is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

BeOne Medicines has a beta of 0.45, indicating that its stock price is 55% less volatile than the S&P 500. Comparatively, Catalyst Pharmaceuticals has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500.

Insider and Institutional Ownership

48.6% of BeOne Medicines shares are held by institutional investors. Comparatively, 79.2% of Catalyst Pharmaceuticals shares are held by institutional investors. 6.6% of BeOne Medicines shares are held by insiders. Comparatively, 10.4% of Catalyst Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings for BeOne Medicines and Catalyst Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	1	1	12	0	2.79
Catalyst Pharmaceuticals	0	2	6	2	3.00

BeOne Medicines presently has a consensus target price of $365.79, suggesting a potential upside of 8.99%. Catalyst Pharmaceuticals has a consensus target price of $32.67, suggesting a potential upside of 43.97%. Given Catalyst Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Catalyst Pharmaceuticals is more favorable than BeOne Medicines.

Summary

Catalyst Pharmaceuticals beats BeOne Medicines on 11 of the 15 factors compared between the two stocks.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.